These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 29464559)

  • 41. Inhibition of monoamine oxidase by benzoxathiolone analogues.
    Mostert S; Petzer A; Petzer JP
    Bioorg Med Chem Lett; 2016 Feb; 26(4):1200-4. PubMed ID: 26821818
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Functional role of the "aromatic cage" in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins.
    Li M; Binda C; Mattevi A; Edmondson DE
    Biochemistry; 2006 Apr; 45(15):4775-84. PubMed ID: 16605246
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
    Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
    Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Monoamine oxidase as a target for drug action].
    Drozak J; Kozłowski M
    Postepy Hig Med Dosw (Online); 2006; 60():498-515. PubMed ID: 17060892
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
    Naoi M; Riederer P; Maruyama W
    J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
    Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
    Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B.
    Binda C; Wang J; Li M; Hubalek F; Mattevi A; Edmondson DE
    Biochemistry; 2008 May; 47(20):5616-25. PubMed ID: 18426226
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Steered molecular dynamics simulations reveal important mechanisms in reversible monoamine oxidase B inhibition.
    Allen WJ; Bevan DR
    Biochemistry; 2011 Jul; 50(29):6441-54. PubMed ID: 21682347
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Mechanistic study of monoamine oxidase: significance for MAO A and MAO B in situ].
    Ramsay RR
    Vopr Med Khim; 1997; 43(6):457-70. PubMed ID: 9503563
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.
    Ramesh M; Dokurugu YM; Thompson MD; Soliman ME
    Comb Chem High Throughput Screen; 2017; 20(6):492-509. PubMed ID: 28294055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities.
    Kumar B; Gupta VP; Kumar V
    Curr Drug Targets; 2017; 18(1):87-97. PubMed ID: 26648064
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of MAO-B inhibitors - present status and future directions part I: oxygen heterocycles and analogs.
    Helguera AM; Perez-Machado G; Cordeiro MN; Borges F
    Mini Rev Med Chem; 2012 Sep; 12(10):907-19. PubMed ID: 22420569
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Use of selective inhibitors for computer modeling of the monoamine oxidase active site].
    Veselovskiĭ AV; Ivanov AS; Medvedev AE
    Vopr Med Khim; 1997; 43(6):527-36. PubMed ID: 9503570
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
    Rojas RJ; Edmondson DE; Almos T; Scott R; Massari ME
    Bioorg Med Chem; 2015 Feb; 23(4):770-8. PubMed ID: 25600407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Inhibition of monoamine oxidase by indole-5,6-dicarbonitrile derivatives.
    Chirkova ZV; Kabanova MV; Filimonov SI; Abramov IG; Petzer A; Petzer JP; Firgang SI; Suponitsky KY
    Bioorg Med Chem Lett; 2015 Mar; 25(6):1206-11. PubMed ID: 25701250
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Exploring the structural basis of the selective inhibition of monoamine oxidase A by dicarbonitrile aminoheterocycles: role of Asn181 and Ile335 validated by spectroscopic and computational studies.
    Juárez-Jiménez J; Mendes E; Galdeano C; Martins C; Silva DB; Marco-Contelles J; do Carmo Carreiras M; Luque FJ; Ramsay RR
    Biochim Biophys Acta; 2014 Feb; 1844(2):389-97. PubMed ID: 24247011
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Structural aspects of monoamine oxidase and its reversible inhibition.
    Wouters J
    Curr Med Chem; 1998 Apr; 5(2):137-62. PubMed ID: 9481038
    [TBL] [Abstract][Full Text] [Related]  

  • 59. cis-Cyclopropylamines as mechanism-based inhibitors of monoamine oxidases.
    Malcomson T; Yelekci K; Borrello MT; Ganesan A; Semina E; De Kimpe N; Mangelinckx S; Ramsay RR
    FEBS J; 2015 Aug; 282(16):3190-8. PubMed ID: 25755053
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monoamine oxidase inhibition by selected anilide derivatives.
    Legoabe L; Kruger J; Petzer A; Bergh JJ; Petzer JP
    Eur J Med Chem; 2011 Oct; 46(10):5162-74. PubMed ID: 21899930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.